Copyright ©The Author(s) 2019.
World J Gastroenterol. May 28, 2019; 25(20): 2416-2429
Published online May 28, 2019. doi: 10.3748/wjg.v25.i20.2416
Table 1 On-going clinical trials for combination of immune checkpoint inhibitor and radiation
NCT numberInstitutionPhaseDiseaseInterventionEstimated enrollmentPrimary endpoint
NCT03482102United States (MGH)IILocally advanced/ unresectable or metastatic disease HCC or biliary tract cancerExperimental: Tremelimumab + Durvalumab + EBRT70Best overall response rate
NCT03203304United States (UCh)IHCCSBRT Nivolumab → +/- ipilimumab + SBRT (8 Gy × 5)50Number of participants with adverse events
NCT03316872Canada (UHN)IIHCC showing progression after sorafenibPembrolizumab + SBRT30Overall response rate
NCT03812562United States (NU)IHCC intended to be resected90Y SIRT → Nivolumab12Recurrence rate
NCT03033446Singapore (NCC)IIHCC not suitable for resection or transplant90Y SIRT → Nivolumab40Response rate
NCT02837029United States (NU)I/IbHCC stage IIIA - IVB90Y SIRT → Nivolumab35Maximum tolerated dose
NCT03099564United States (UNC)IHCC90Y SIRT + Pembrolizumab30Progression-free survival